NovaBay Pharmaceuticals Partnership Strategy Ou
Post# of 52
NovaBay Pharmaceuticals Partnership Strategy
Our lead product candidate, NVC-422, as well as many of the product candidates we expect to develop in the future, are primarily intended to address a variety of different non-systemic market segments, some of which are large, primary care markets. We do not currently have, nor do we intend in the near term to create, a commercialization organization capable of marketing, selling and distributing our targeted product candidates to large, primary care markets. This applies to markets in both the United States and elsewhere. Rather, we intend to establish commercialization partnerships with pharmaceutical, biotechnology or other leading organizations with the experience and resources to bring our products to market. In some cases, we may enter into agreements with these organizations during the development stage of a product candidate to benefit further from their clinical development, regulatory, market research, pre-marketing and other expertise, as is the case with Galderma. As appropriate, we may establish a specialty sales force with expertise in marketing and selling any future approved products to specialty physicians for specific target indications. We may also establish other complementary capabilities related to marketing and selling targeted medicines, particularly where those capabilities may not currently exist at other organizations. Substantially all of our long-lived assets are located in the United States.
Galderma
Galderma, a leading global pharmaceutical company dedicated exclusively to the field of dermatology, signed a collaboration and licensing agreement with NovaBay in March 2009. Galderma and NovaBay are working together to research, develop and commercialize NovaBay’s Aganocide compounds to treat all major dermatological conditions, excluding onychomycosis (nail fungus).
December 6, 2010
NovaBay Pharmaceuticals, Inc. and Galderma Expand Their Agreement to Include Impetigo
Partnered Products
| Product | Indication | Market Size | Clinical Status | Licensee |
| NVC-422 | Impetigo | ~13M Rx written in 2009 | Phase 2 | Galderma |
* Galderma Partnership: NBY Retains some rights in Asia
Partnership Opportunities
The following license/collaboration opportunities are available:
NVC-422:
• Urinary catheter irrigation solution for Urinary Catheter Blockage and Encrustation: Phase 2 stage
• Eye drops for viral conjunctivitis: Phase 2 stage
• Topical gel for onychomicosis: Preclinical stage
• Topical form for chronic sinusitis: Preclinical stage
NeutroPhase:
• Marketing/Distribution partner for US: 510k cleared for wound care
• Ex-US regional marketing/distribution partners: pre-registration stage
(0)
(0)